Tarnagulla Ventures
Venture capitalMelbourne · Pre-Seed–Series A · 2 people tracked
Investment thesis
Tarnagulla Ventures is an exclusively life science and healthcare investor, providing seed and early-stage venture capital to promising companies. It follows a concentrated, low-frequency investment approach, favoring fewer but deeper commitments so it can dedicate significant time to nurturing portfolio companies with strategic support. Beyond financial capital, the firm emphasizes contributing intellectual capital drawn from its experience in small molecule, protein, and cell-based therapeutics. As value investors, it treats the initial investment as the beginning of a long-term partnership. Although headquartered in Melbourne, Australia, most of its investments are in US-based companies, and it focuses on bringing medical technology to Australian and US markets.
Source: firm website, verified Aug 3, 2026.
Team · 2 people
from the firm's website
What they invest in
from 4 of 7 portfolio companiesBiotech ×4Healthtech ×2Medical Devices ×2Digital Health ×1
HQs:United States×3
Investments · 7 tracked
founders shown can be your intro pathClinical-stage specialty pharmaceutical company developing therapies for rare single-gene-deficiency diseases, including its JOTROL formulation of Resveratrol.
LB Pharma develops novel therapies for neuropsychiatric disorders, with a lead product candidate called LB-102, an oral small molecule benzamide antipsychotic targeting schizophrenia, bipolar depression, and other neuropsychiatric diseases.
BiotechDigital HealthNew York, US
Zachary Prensky(Executive Officer, Director)Lauren Stipp(Executive Officer)Mark Panoff(Executive Officer)
BoardEdmund Sullivan(Director)Vincent Grattan(Director)
Co-investorsPontifax Venture CapitalVida VenturesTCG Crossover
BiotechEncino, US
Matthew Davidson(Executive Officer, Director)
BoardDennis Brown(Director)
Portfolio company acquired by Novo Nordisk for $1.1B USD.
Co-investorsAmorChemGenesys CapitalJDRF T1D Fund
Lübris BioPharma develops recombinant human lubricin for treating dry eye, osteoarthritis, and age/inflammation-related conditions.
BiotechHealthtechMedical Devices
Co-investorsThynk Capital
Nacuity develops targeted therapies aimed at stopping oxidative tissue damage, a driver of blinding eye diseases and other chronic conditions.
BiotechHealthtechMedical DevicesFort Worth, US
Michael Wall(Executive Officer)David Wohlberg(Executive Officer, Director)Jami Kern(Executive Officer)Halden Conner(Executive Officer, Director)Charles Lieser(Executive Officer)
BoardEmmett Cunningham, Jr.(Director)
Develops science-based probiotic biotherapeutics to support maternal microbiome health during pregnancy and reduce infant food allergy risk.
Exits · 3
IPOs and acquisitions across the tracked portfolioJupiter Neurosciences, Inc.NASDAQ: JUNSLbpharmaNASDAQ: LBRXInversagoacq. by Novo Nordisk
Frequently asked questions
- How many investments has Tarnagulla Ventures made?
- Tarnagulla Ventures has 7 tracked investments, 1 of which have exited via acquisition or IPO.
- What stage does Tarnagulla Ventures invest at?
- Tarnagulla Ventures invests at the Pre-Seed, Seed, Series A stages.
- What sectors does Tarnagulla Ventures focus on?
- Tarnagulla Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Tarnagulla Ventures located?
- Tarnagulla Ventures is headquartered in Melbourne, AU.
- Who does Tarnagulla Ventures co-invest with?
- Tarnagulla Ventures most often shares deals with Genesys Capital, JDRF T1D Fund, Pontifax Venture Capital, among 6 tracked co-investors.
Similar investors
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
MedMountain Ventures (MMV) is an early-stage healthcare investment firm founded by board-certified physicians and seasoned healthcare operators, backing companies that improve patient outcomes and reshape how care is delivered, financed, and accessed.
Snatched Ventures is a San Francisco-based early-stage venture capital firm backing DeepTech startups focused on sustainable innovation and operational transformation. It is led by a two-GP team combining corporate development and institutional investment management experience.
The Vertical Group is a venture capital firm focused on medical technology and biotechnology. Independent since 1988, it is the successor to the venture capital division of F. Eberstadt & Co.
View Ventures is an early-stage investor focused on medical and health technology companies.